Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
I. Migdalis, A. Efthimiadis, St. Pappas, D. Alexopoulos, F. Vlasserou & D. P. Mikhailidis. (2009) Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Current Medical Research and Opinion 25:10, pages 2571-2576.
Read now
Read now
CS Derdemezis, TD Filippatos, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opinion on Pharmacotherapy 9:11, pages 1829-1837.
Read now
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Read now
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, pages 995-1009.
Read now
Read now
Kosmas I. Paraskevas & Dimitri P. Mikhailidis. (2008) C-reactive protein (CRP): more than just an innocent bystander?. Current Medical Research and Opinion 24:1, pages 75-78.
Read now
Read now
Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis & Dimitri P Mikhailidis. (2007) Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opinion on Therapeutic Targets 11:9, pages 1143-1160.
Read now
Read now
D. P. Mikhailidis, G. C. Sibbring, C. M. Ballantyne, G. M. Davies & A. L. Catapano. (2007) Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current Medical Research and Opinion 23:8, pages 2009-2026.
Read now
Read now
Mihalis Kalogirou, Vasilis Tsimihodimos, Irene Gazi, Theodosios Filippatos, Vasilis Saougos, Alexandros D. Tselepis, Dimitri P. Mikhailidis & Moses Elisaf. (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Current Medical Research and Opinion 23:5, pages 1169-1176.
Read now
Read now
Articles from other publishers (19)
Peeyush Jain. (2023) Traditional and novel non-statin lipid-lowering drugs. Indian Heart Journal.
Crossref
Crossref
Panagiotis Anagnostis, Vasileios Kotsis, Maciej Banach & Dimitri P. Mikhailidis. (2023) Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?. Metabolites 13:2, pages 145.
Crossref
Crossref
Zijuan Wu, Danling Gu, Ruixin Wang, Xiaoling Zuo, Huayuan Zhu, Luqiao Wang, Xueying Lu, Yi Xia, Shuchao Qin, Wei Zhang, Wei Xu, Lei Fan, Jianyong Li & Hui Jin. (2022) CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Jeonghyeon Moon, Seon-Yeong Lee, Hyun Sik Na, A Ram Lee, Keun-Hyung Cho, Jeong Won Choi, Sung-Hwan Park & Mi-La Cho. (2022) Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation. Frontiers in Immunology 13.
Crossref
Crossref
Li Qin, Yun-Bo Yang, Yi-Xin Yang, Neng Zhu, Shun-Xiang Li, Duan-Fang Liao & Xi-Long Zheng. (2014) Anti-Inflammatory Activity of Ezetimibe by Regulating NF-κB/MAPK Pathway in THP-1 Macrophages. Pharmacology 93:1-2, pages 69-75.
Crossref
Crossref
E. Scorletti, P. C. Calder & C. D. Byrne. (2011) Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40:3, pages 332-343.
Crossref
Crossref
Lívia Bracht, Silvana Martins Caparroz-Assef, Thiago Ferreira dos Santos Magon, Alessandra Mileni Versuti Ritter, Roberto Kenji Nakamura Cuman & Ciomar Aparecida Bersani-Amado. (2011) Topical anti-inflammatory effect of hypocholesterolaemic drugs. Journal of Pharmacy and Pharmacology 63:7, pages 971-975.
Crossref
Crossref
Michalis Kalogirou, Vasilis Tsimihodimos & Moses Elisaf. (2010) Pleiotropic effects of ezetimibe: Do they really exist?. European Journal of Pharmacology 633:1-3, pages 62-70.
Crossref
Crossref
Peggy Kostakou, Genovefa Kolovou, Katherine Anagnostopoulou, Theodor Theodoridis, Vassiliki Galea, Constantinos Mihas, Vassiliki Christopoulou-Cokkinou & Dennis V. Cokkinos. (2010) Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. Archives of Cardiovascular Diseases 103:1, pages 26-32.
Crossref
Crossref
Kosmas I. Paraskevas, Daryll M. Baker, Alfonso Pompella & Dimitri P. Mikhailidis. (2008) Does Diabetes Mellitus Play a Role in Restenosis and Patency Rates Following Lower Extremity Peripheral Arterial Revascularization? A Critical Overview. Annals of Vascular Surgery 22:3, pages 481-491.
Crossref
Crossref
Anne Braun, Ayce Yesilaltay, Susan Acton, Kay O. Broschat, Elaine S. Krul, Nida Napawan, Nancy Stagliano & Monty Krieger. (2008) Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis 198:1, pages 77-84.
Crossref
Crossref
Kosmas I. Paraskevas, Daryll M. Baker, Alfonso Pompella & Dimitri P. Mikhailidis. (2008) ¿Qué papel desempeña la diabetes mellitus en las tasas de reestenosis y permeabilidad tras la revascularización infrainginal? Revisión crítica. Anales de Cirugía Vascular 22:3, pages 525-536.
Crossref
Crossref
Kosmas I. Paraskevas, Daryll M. Baker, Alfonso Pompella & Dimitri P. Mikhailidis. (2008) Le diabète joue-t-il un rôle dans les resténoses et les taux de perméabilité après revascularisation artérielle des membres inferieurs ? une étude générale critique. Annales de Chirurgie Vasculaire 22:3, pages 521-532.
Crossref
Crossref
Enrique González-Sarmiento, José Zurrohernández & E. Inmaculada Fernández-Galante. (2008) Efectividad de ezetimiba en la práctica clínica habitual. Efecto en el perfil lipídico y otros parámetros analíticos. Endocrinología y Nutrición 55:4, pages 165-169.
Crossref
Crossref
M. Florentin, E. N. Liberopoulos & M. S. Elisaf. (2007) Ezetimibe-associated adverse effects: what the clinician needs to know. International Journal of Clinical Practice 62:1, pages 88-96.
Crossref
Crossref
G. E. Vrentzos, J. A. Papadakis, E. S. Ganotakis, K. I. Paraskevas, I. F. Gazi, N. Tzanakis, D. R. Nair & D. P. Mikhailidis. (2007) Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease. International Journal of Clinical Practice 61:10, pages 1643-1653.
Crossref
Crossref
Shingo Sakamoto, Hiroyuki Kusuhara, Kenji Miyata, Hiroyuki Shimaoka, Takushi Kanazu, Yumiko Matsuo, Kohji Nomura, Noboru Okamura, Seijiro Hara, Kazutoshi Horie, Takahiko Baba & Yuichi Sugiyama. (2007) Glucuronidation Converting Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a Potent Apical Sodium-Dependent Bile Acid Transporter Inhibitor, Resulting in a Hypocholesterolemic Action. Journal of Pharmacology and Experimental Therapeutics 322:2, pages 610-618.
Crossref
Crossref
Gerd Schmitz, Anna Schmitz-Mądry & Peter Ugocsai. (2007) Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Current Opinion in Lipidology 18:2, pages 164-173.
Crossref
Crossref
Dibyendu De & Ish Khanna. 2007. Annual Reports in Medicinal Chemistry Volume 42. Annual Reports in Medicinal Chemistry Volume 42
177
191
.